| |
|
|
|
|
|
 |
| |
|
À¯µ¥¹ÎÁ¤ EUDEMIN TABLET[Diazoxide]
|
|
ÀϹÝÀǾàǰ | ¹Ì»ý»ê
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100's |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ¿¡ ÀÇÇÑ ½ÉÇÑ Áõ»óÀ» µ¿¹ÝÇÏ´Â ³Ä¡¼º ÀúÇ÷´ç : Ư¹ß¼º ¼Ò¾Æ ÀúÇ÷´ç, ·ù½Å °¨¼ö¼º ÀúÇ÷´ç ¹× ºÐ·ùµÇÁö ¾ÊÀº ÀúÇ÷´ç, ¼ö¼ú ºÒ´ÉÀÇ ¾Ç¼º ¹× ¾ç¼º Ãéµµ¼¼Æ÷Á¾, ÀúÇ÷´çÀ» À¯¹ßÇÏ´Â ÃéÀå¿Ü Á¾¾ç, ±Û¸®ÄÚ°Õ ÀúÀåÀÌ»ó, ¿øÀκҸíÀÇ ÀúÇ÷´ç
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ÃʱâÅõ¿©·®Àº 5mg/kg/dayÀÇ ¿ë·®À¸·Î 1ÀÏ 2-3ȸ µ¿·® ºÐÇÒÅõ¿©ÇÑ´Ù. ÀÌÈÄ Áõ»ó¿¡ µû¶ó Ç÷´çÀÌ ¸¸Á·ÇÒ¸¸ÇÏ°Ô »ó½ÂµÉ¶§±îÁö Áõ·®ÇÑ´Ù. ·ù½Å°¨¼ö¼º ÀúÇ÷´ç½Ã ¼Ò¾Æ¿ë·®Àº 15-20mg/kg/day¸¦ Åõ¿©ÇÑ´Ù. ´Ù·®ÀÇ Àν¶¸°À» ºÐºñÇÏ´Â ¾ç¼º ¹× ¾Ç¼º Ãéµµ¼¼Æ÷Á¾¿¡ ´ëÇÑ ¼ºÀÎ ¿ë·®Àº 1ÀÏ 1000mg±îÁö Áõ·®°¡´ÉÇÏ´Ù.
|
| ±Ý±â |
¼ö¼úÀûÀ¸·Î ¶Ç´Â ´Ù¸¥ Ä¡·á¹ý¿¡ ÀÇÇÏ¿© ÀúÇ÷´çÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â ¸ðµç °æ¿ì, º»Á¦ ¹× ´Ù¸¥ Ä¡¾ÆÁþ°è ¾à¹°¿¡ ´ëÇÑ °ú¹ÎÇÑ È¯ÀÚ. |
| ½ÅÁßÅõ¿© |
°í´¢»êÇ÷Áõ ¹× Åëdz ±â¿Õ·ÂÀÚ, ½ÅÀå¾ÖȯÀÚ |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| BIT ¾àÈ¿ºÐ·ù |
±âŸ Ç÷¾× ¹× Á¶Ç÷±â°ü °ü·Ã ¾à¹° (Other Blood & Hematopoietic Related Agents)
|
| ATC ÄÚµå |
Diazoxide / V03AH01
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
399 (µû·Î ºÐ·ùµÇÁö ¾Ê´Â ´ë»ç¼º ÀǾàǰ )
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Diazoxide¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Diazoxide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ As a diuretic, diazoxide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like diazoxide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of diazoxide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. As a antihypoglycemic, diazoxide inhibits insulin release from the pancreas, probably by opening potassium channels in the beta cell membrane.
|
| Pharmacology |
Diazoxide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diazoxide is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.
|
| Metabolism |
Diazoxide¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Diazoxide¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Very high (more than 90%) to serum proteins.
|
| Half-life |
Diazoxide¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 28 ¡¾8.3 hours in normal adults.
|
| Absorption |
Diazoxide¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed following oral administration.
|
| Pharmacokinetics |
DiazoxideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Ç÷´ç»ó½ÂÀÛ¿ë
- °æ±¸
- ÀÛ¿ë¹ßÇö½Ã°£ : 1½Ã°£ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£(Á¤»ó ½Å±â´É) : 8½Ã°£
- Ç÷¾Ð°ÇÏÀÛ¿ë
- Á¤¸ÆÁÖ»ç
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£ : 5ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : º¸Åë 3-12½Ã°£
- ´Ü¹é°áÇÕ : 90%
- ¹Ý°¨±â
- ¼Ò¾Æ : 9-24½Ã°£
- ¼ºÀÎ : 20-36½Ã°£
- ¸»±â ½ÅÁúȯ ȯÀÚ : 30½Ã°£ ÀÌ»ó
- ¼Ò½Ç : 50%°¡ ¼Òº¯À¸·Î ¹Ìº¯Èü·Î ¹è¼³µÊ
|
| Biotransformation |
Diazoxide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Diazoxide¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral LD50 in rat and mouse: 980 mg/kg and 444 mg/kg, respectively.
|
| Drug Interactions |
Diazoxide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Diazoxide¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Diazoxide¿¡ ´ëÇÑ Description Á¤º¸ A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. [PubChem]
|
| Dosage Form |
Diazoxide¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Diazoxide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypertensive AgentsDiuretics, ThiazideVasodilator Agents
|
| Smiles String Canonical |
Diazoxide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2
|
| Smiles String Isomeric |
Diazoxide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2
|
| InChI Identifier |
Diazoxide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)/f/h10H
|
| Chemical IUPAC Name |
Diazoxide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 7-chloro-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2013-10-04
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|